SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (“BSD”) (NASDAQ:BSDM) today reported clinical study data showing that hyperthermia, using the BSD-2000 Hyperthermia System, combined with chemotherapy has the potential to improve control rate and long-term survival for the treatment of children with high-risk cancer who have a dismal prognosis.
